Foliglurax (developmental code names PXT-002331, DT2331) is a
positive allosteric modulator
In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimulus. Some of them, like benzodiazepines, are drugs. The site that an allosteric modulator binds to ...
of the
metabotropic glutamate receptor 4
Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the ''GRM4'' gene.
Together with GRM6, GRM7 and GRM8 it belongs to group III of the metabotropic glutamate receptor family. Group III receptors are linked to the inhibi ...
(mGluR
4),
which is under development by Prexton Therapeutics for the treatment of
Parkinson's disease
Parkinson's disease (PD), or simply Parkinson's, is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms becom ...
.
It reached
phase II clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s,
but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distingush itself from placebo to meet the study endpoints.
References
Benzopyrans
Experimental drugs
MGlu4 receptor agonists
4-Morpholinyl compunds
Nitroso compounds
Thienopyridines
{{Nervous-system-drug-stub